search
Back to results

Sodium Lactate Infusion in GLUT1DS Patients

Primary Purpose

GLUT1 Deficiency Syndrome, GLUT1DS1, GLUT1DS2

Status
Completed
Phase
Early Phase 1
Locations
Netherlands
Study Type
Interventional
Intervention
sodiumlactate
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for GLUT1 Deficiency Syndrome focused on measuring GLUT1 deficiency syndrome, sodium lactate infusion, epilepsy

Eligibility Criteria

6 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosed with GLUT1DS and known in our center.
  • Baseline characteristics include a high frequency of clinical seizures and epileptic discharges on EEG.
  • History of trying ketogenic diet with good compliance without beneficial effects.
  • Age > 6 years.
  • Informed consent.

Exclusion Criteria:

  • Additional medical condition or illness that impairs the patient's ability to participate in the study (for example actual treatment of a malignancy, active infection, poorly controlled diabetes mellitus, hypertension, organ failure, clinically significant haematological or biochemical abnormalities).
  • Elevated serum sodium (> 145 mmol/L).
  • Participation in another interventional study at start of the study or during the study.
  • Presence of known panic disorders or a history of panic attacks.

Sites / Locations

  • Radboudumc

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention

Arm Description

three GLUT1DS patients with drug resistant epilepsy who tried the ketogenic diet without any benefits.

Outcomes

Primary Outcome Measures

Number of changes in epileptic discharges on EEG during the infusion of lactate.
All subjects have frequent epileptic discharges on EEG. We want to objectify the change in epileptic discharges on EEG during and after the infusion of sodium lactate.

Secondary Outcome Measures

Change in seizure frequency clinical visible by caregivers during and after infusion of sodium lactate.
All subjects have frequent seizures, we want to see if these clinically visible seizures reduce during or after infusion with sodium lactate.
Concentration of lactate in blood during and after sodium lactate infusion
Concentration of glucose in blood during and after sodium lactate infusion
Concentration of sodium in blood during and after sodium lactate infusion
Concentration of potassium in blood during and after sodium lactate infusion
Concentration of bicarbonate in blood during and after sodium lactate infusion
Concentration of chloride in blood during and after sodium lactate infusion
pH in blood during and after sodium lactate infusion

Full Information

First Posted
September 18, 2019
Last Updated
November 22, 2022
Sponsor
Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04112862
Brief Title
Sodium Lactate Infusion in GLUT1DS Patients
Official Title
Effects of Sodium Lactate Infusion in Patients With Glucose Transporter 1 Deficiency Syndrome (GLUT1DS)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
May 20, 2022 (Actual)
Primary Completion Date
November 18, 2022 (Actual)
Study Completion Date
November 18, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study investigates the effect of lactate infusion on epileptic discharges on EEG and seizure frequency in glucose transporter 1 deficiency syndrome (GLUT1DS) patients.
Detailed Description
In glucose transporter 1 deficiency syndrome (GLUT1DS) cerebral glucose uptake from the systemic blood circulation is limited, because of deficient transport of glucose across the blood-brain barrier by the transporter protein (GLUT1). Classically patients present with developmental problems, movement disorders and severe epilepsy. There is no curative treatment for GLUT1DS, and anti-epileptic drugs usually have little to no effect. The ketogenic diet, providing ketones as an alternative energy substrate for the brain is an effective treatment option for the epilepsy and movement disorders in many GLUT1DS patients. Unfortunately, not in all GLUT1DS patients the ketogenic diet has a positive effect and other treatment options for these patients are very limited. Traditionally, lactate is seen as a waste product of glycolysis during anaerobic conditions and a marker of ischemia. Interestingly, research has shown the beneficial side of lactate as an energy source for different organs. It seems that the brain can indeed use lactate as an alternative energy metabolite, besides glucose and ketones. The aim of this study is to investigate whether lactate can be an alternative energy metabolite in the GLUT1DS brain, and reduce epileptic discharges on EEG when intravenously administered in patients with GLUT1DS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
GLUT1 Deficiency Syndrome, GLUT1DS1, GLUT1DS2, Epilepsy, Lactic Acid Blood Increased, Ketogenic Dieting
Keywords
GLUT1 deficiency syndrome, sodium lactate infusion, epilepsy

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Model Description
Single center, interventional, explorative, open label, proof of principle study
Masking
None (Open Label)
Allocation
N/A
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
three GLUT1DS patients with drug resistant epilepsy who tried the ketogenic diet without any benefits.
Intervention Type
Other
Intervention Name(s)
sodiumlactate
Intervention Description
intravenous sodiumlactate 600mmol/L
Primary Outcome Measure Information:
Title
Number of changes in epileptic discharges on EEG during the infusion of lactate.
Description
All subjects have frequent epileptic discharges on EEG. We want to objectify the change in epileptic discharges on EEG during and after the infusion of sodium lactate.
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Change in seizure frequency clinical visible by caregivers during and after infusion of sodium lactate.
Description
All subjects have frequent seizures, we want to see if these clinically visible seizures reduce during or after infusion with sodium lactate.
Time Frame
1 day
Title
Concentration of lactate in blood during and after sodium lactate infusion
Time Frame
1 day
Title
Concentration of glucose in blood during and after sodium lactate infusion
Time Frame
1 day
Title
Concentration of sodium in blood during and after sodium lactate infusion
Time Frame
1 day
Title
Concentration of potassium in blood during and after sodium lactate infusion
Time Frame
1 day
Title
Concentration of bicarbonate in blood during and after sodium lactate infusion
Time Frame
1 day
Title
Concentration of chloride in blood during and after sodium lactate infusion
Time Frame
1 day
Title
pH in blood during and after sodium lactate infusion
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with GLUT1DS and known in our center. Baseline characteristics include a high frequency of clinical seizures and epileptic discharges on EEG. History of trying ketogenic diet with good compliance without beneficial effects. Age > 6 years. Informed consent. Exclusion Criteria: Additional medical condition or illness that impairs the patient's ability to participate in the study (for example actual treatment of a malignancy, active infection, poorly controlled diabetes mellitus, hypertension, organ failure, clinically significant haematological or biochemical abnormalities). Elevated serum sodium (> 145 mmol/L). Participation in another interventional study at start of the study or during the study. Presence of known panic disorders or a history of panic attacks.
Facility Information:
Facility Name
Radboudumc
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500GA
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
We want to include three patients, who all are there own control. If one of their EEGs shows interesting changes during or after lactate infusion, we plan to describe that in our article.

Learn more about this trial

Sodium Lactate Infusion in GLUT1DS Patients

We'll reach out to this number within 24 hrs